Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing
(OTCQB:NBIO),(OTC US:NBIO), NORTH PALM BEACH, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) — Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology company developing monoclonal antibodies targeting various cancer types, today announced that it has received a written notification from the OTC Markets Group as a result of its failure to file […]